SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Want to cut your energy bills? Here’s how five experts are doing it 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
GAITHERSBURG, Md., March 30, 2016 -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in Needham & Company’s 15th Annual Healthcare Conference, April 12-13, 2016 in New York, NY.
Presentation date and time will be updated on the Emergent website www.emergentbiosolutions.com under “Investors” as this information becomes available.
For this conference, the company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcast will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions Inc.
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3394 [email protected]
